Fig. 5: Identification of biologically active doses of IMC-M113V.
a Serum IL-6 was quantified in samples obtained pre-infusion, 8 and 24 h and 7 days post-infusion. Each line represents an individual study participant. The lower limit of quantification (2.5 pg/mL) is indicated by a dotted line. b IMC-M113VRES binding affinity (37 °C) was determined for Gag77–85 variants identified in pre-dose HIV cell-associated RNA (CA-RNA) extracted from participants’ peripheral blood CD4+ cells (15 µg cohort). The dominant sequence for each participant is shown. Relative frequencies of identified variants are shown in Supplementary Fig. 6. c Peak serum IL-6 response was plotted against pre-dose HIV CA-RNA value. Participants with picomolar and nanomolar affinity viral variants are indicated in pink and blue, respectively. d Expression of T cell activation and cytolytic molecules pre- and 24 h post-dosing with IMC-M113V (15 µg): PBMCs collected pre-dose (blue bars) and 24 h post-dose (green bars) were stained for surface markers (n = 6) or stimulated ex vivo with PMA and ionomycin in the presence of brefeldin A (n = 5). Percentage of positively stained cells (left y axes) and mean fluorescence intensities (MFI, right y axes) are shown for CD69 (top left), interferon-gamma (IFN-γ, top right), granzyme B (GzB, bottom left) and perforin (bottom right). Circles represent percentage positivity or MFI of individual participants, whilst bars represent mean values. A two-sided paired t-test was used to compare pre-dose and post dose groups; p values < 0.05 were considered statistically significant.
